TORONTO– Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND), a leading biotech company in fast-acting psychedelics is pleased to announce that it has filed a patent application in the United States Patent and Trademark Office (USPTO), its 4th patent application.
“As we advance in the development of our proprietary line of novel pharmaceuticals, we have filed a new patent application, enabling us to continue building a robust IP strategy. Our focus on our main pillar, fast-acting psychedelics, resides on two tryptamines, N,N-Dimethyltryptamine (DMT) and 5-methoxy-N,N- dimethyltryptamine (5-MeO-DMT), two molecules that have the potential to allow us to cross the barrier of 60 minutes on treatments that require a full psychedelic experience. This aligns with our second pillar – affordability. Patients are everything for us, meaning that our novel pharmaceuticals are being developed for all patients that require an alternative medication to traditional anti-depressants, regardless of income level”, said Alejandro Antalich, CEO of Biomind Labs.
The patent application filed in the USPTO relates to Biomind Labs’ proprietary technology on labeled DMT and an associated method for a personalized treatment of neurological and psychiatric disorders. The method monitors DMT levels in relevant body fluids facilitating the design of personalized treatments, regardless of metabolic, genetic, or environmental factors. Further, it is a novel method that allows the development of DMT based treatments available to the modern psychiatric clinical practice.
Biomind is a biotech research and development company aimed at transforming biomedical sciences knowledge from natural psychotropic plants into novel pharmaceutical drugs and innovative nanotech delivery systems for a variety of psychiatric and neurological conditions. Through its acceleration platform, Biomind is developing novel pharmaceutical formulations of the main natural psychedelic molecules, N, N-dimethyltryptamine (DMT), 5-MeO-DMT and mescaline for treating a wide range of therapeutic indications. Biomind’s focus is to guarantee patients access to affordable and modern-day treatments and use cases. Biomind understands that long-lasting psychedelic effects make it difficult to create adequate clinical protocols to serve a larger number of patients, and this is the reason why Biomind specializes in fast-acting psychedelics.
